Patients & Caregivers
Otoprotectant Properties of Sodium Thiosulfate: Results of the SIOPEL 6 Study
In the cisplatin alone group, 67% of patients showed signs of hearing loss compared to only 37% in the cisplatin + sodium thiosulfate group.
Hearing Loss, Isolation, and Ludwig van Beethoven
the isolation that patients can feel when they lose their sense of hearing was well described by the composer, Ludwig van Beethoven.
Hearing Loss is Exhausting
The energy a hearing-impaired person needs to listen can be exhausting.
8 Friends Needed to Help 1 Hearing-impaired Person
Caroline has profound hearing loss as a result of the chemotherapy she needed to combat the neuroblastoma she had as a child.
Cancer Treatment and Hearing Loss: Winning the Battle But Losing The War
While he was once a gregarious, out-going boy, he is now lonely and frustrated because he can not keep up with the conversations.
A Little Hearing Loss is a Big Deal
Numerous social and psychological problems can stem from a little hearing loss that can profoundly impact a child growing up.
Quality of Life in Children with Hearing Loss Following Chemotherapy
Rare Disease Report
spoke with Dr. Rajput about her research that displays the profound impact that hearing loss had on the quality of life.
Cisplatin-associated Hearing Loss in Children - The Past, Present, and Future
Until recently, the only option was to accept hearing loss a side effect of being cured of cancer. New options are becoming available.
Fibrolamellar Cancer Foundation Leads the Way During Liver Cancer Awareness Month
October is Liver Cancer Awareness month, and the Fibrolamellar Cancer Foundation is making sure the world's fifth most common cancer type is properly recognized.
FDA Fast Tracks Astellas' AML Treatment
This morning, Astellas announced that it was granted Fast Track designation for the development of gilternitinb in adult patients with AML.
<< Prev Page
Next Page >>
STRATEGIC ALLIANCE PARTNERSHIP PROGRAM >
Familial Chylomicronemia Syndrome
MJH ASSOCIATES >
Specialty Pharmacy Times
Terms & Conditions
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.